Vimarsana
Biggest News Aggregation in the World

Page 2 - About Lung News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from About Lung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In About Lung Today - Breaking & Trending Today

Novartis Pharma AG: Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC - Vimarsana News

Novartis Pharma AG: Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer - Vimarsana News

Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer 1 non-small cell lung cancer 2,3 help 1 beta (IL-1ß) in pro-tumor inflammation i n lung cancer, with multiple clinical trials investigating canakinumab in 2 -5 Basel, March 9, 2021 - Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1ß), in combination with the chemotherapy agent docetaxel, did not meet its primary endpoin...

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer - Vimarsana News

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

19. More people die of lung cancer every year than any other cancer type 11. Novartis is committed to developing best-in-class treatments for lung cancer patients around the world. With a focus on both targeted, personalized medicine and the role of newer, immuno-oncology therapies, the lung cancer drug development program at Novartis is among the most robust in the industry. With research activities informed by long-term relationships with leading lung cancer thought leaders and patient advocates, Novartis is focused on reimagining the treatment of lung cancer.   Disclaimer This press r...

HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo's Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC - Vimarsana News

HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo's Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC

Press release content from Business Wire. The AP news staff was not involved in its creation. HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC February 3, 2021 GMT TOKYO & BASKING RIDGE, N.J. & MUNICH--(BUSINESS WIRE)--Feb 3, 2021-- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient has been dosed in HERTHENA-Lung01, a phase 2 study evaluating patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate (ADC), in patients with epidermal growth factor receptor (EGFR)-mut...

Source: apnews.com